List of Opana Er drug patents
Opana Er is owned by Endo Pharms.
Opana Er contains Oxymorphone Hydrochloride.
Opana Er has a total of 11 drug patents out of which 0 drug patents have expired.
Opana Er was authorised for market use on 22 June, 2006.
Opana Er is available in tablet, extended release;oral dosage forms.
Opana Er can be used as relief of moderate to severe pain, dose modification for renal impairment.
The generics of Opana Er are possible to be released after 22 November, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7851482 | ENDO PHARMS | Method for making analgesics |
Jul, 2029
(6 years from now) | |
| US8871779 | ENDO PHARMS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8329216 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(4 days from now) | |
| US8309112 | ENDO PHARMS | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
Feb, 2023
(4 days from now) | |
| US8309122 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(4 days from now) | |
| US7276250 | ENDO PHARMS | Sustained release formulations of oxymorphone |
Feb, 2023
(4 days from now) | |
| US8075872 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(9 months from now) | |
| US8309060 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(9 months from now) | |
| US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(1 year, 6 months from now) | |
| US8192722 | ENDO PHARMS | Abuse-proof dosage form |
Sep, 2025
(2 years from now) | |
| US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(4 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: Relief of moderate to severe pain; Dose modification for renal impairment
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic